Home

From development to market,
ABL provides GMP viral vectors,
contributing to the success of
our clients’ immunotherapy innovations.

We are a pure play CDMO, specialized in development and GMP manufacturing of viral vectors.

We can help guide you through your process development, tech transfer, validation and QA, all the way to a complete CMC package and documentation

Our European sites are GMP certified

Vaccines

Oncolytic (Virotherapies)

Other Immunotherapies

ABL

An Institut Mérieux Company

We have been a pioneer in developing and producing viral vectors since 1994.

We are grounded in the Mérieux family’s legacy of biology and vaccine expertise since 1897.

As a pure CDMO player, we contribute to the success of your immunotherapy innovations.

  • 1994
    first viral vector facility in Europe
  • 4
    facilities
    (France & USA)
  • ~320
    employees
  • >25
    years of experience
    in viral vectors (manufacturing)
  • Fill & finish up to
    10,000
    vials/batch

ABL
Your solution provider

Please accept marketing cookies to watch this video.

Services